
Please try another search
Reunion Neuroscience Inc. operates as a clinical-stage biopharmaceutical company that develops serotonergic psychedelic therapeutic solutions for mental health disorders, including postpartum depression (PPD) and adjustment disorder (AjD). It offers RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It also develops the RE200 series, which includes preclinical compounds with enhanced receptor selectivity to address additional therapeutic applications. Reunion Neuroscience Inc. was formerly known as Field Trip Health Ltd. and changed its name to Reunion Neuroscience Inc. in June 2021. The company was incorporated in 2008 and is based in Toronto, Canada.
Name | Age | Since | Title |
---|---|---|---|
Yvan Beaussant | - | 2025 | Member of Advisory Board |
Rachel Yehuda | - | 2025 | Member of Advisory Board |
Jerrold F. Rosenbaum | - | 2025 | Member of Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review